The network contained clusters of drugs that were designed to inhibit important oncogenic and cancer progression pathways, such as MEK inhibitors (e.g. selumetinib and cobimetinib) with genes in the BRAF-MAPK pathway (e.g. BRAF, MAPK1 and MAP2K1) and inhibitors of the ErbB family (gefitinib, osimertinib and dacomitinib) (Supplementary Fig. S3). Here, MAP2K1 is linked to cancer.